Bristol-Myers Squibb Company (BMY) said Wednesday its Opdivo drug significantly increased the overall survival of patients with resectable non-small cell lung cancer combined with chemotherapy, compared to those that underwent chemotherapy only.
This was from the company's analysis of the results of its phase 3 Checkmate -816 study, which was a key secondary endpoint of the study. It also builds on the successful primary endpoints of the study with regard to event-free survival and pathological complete response.
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to use the body's own immune system to help restore anti-tumor immune response.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.